leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...126127128129130131132133134135136...235236»
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. (Pubmed Central) -  Aug 8, 2021   
    The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients with metastatic colorectal cancer (mCRC) who progressed after receiving a standard oxaliplatin-based regimen...The majority of patients had multi-organ metastases (73.5%), and had previously received bevacizumab in combination with chemotherapy (CT) as first-line treatment (79.6%)...Neutropenia was the most frequently observed hematological G3-4 AE with an incidence of 10.2%. Aflibercept-FOLFIRI has been confirmed as a feasible second-line treatment for mCRC in a re-al-life setting, and PFS in first-line therapy >12 months resulted as the only predictive marker of better survival.
  • ||||||||||  oxaliplatin / Generic mfg.
    Biomarker, Review, Journal:  Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. (Pubmed Central) -  Aug 7, 2021   
    The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. (Pubmed Central) -  Aug 6, 2021   
    Median csRDIs were 81%, 79%, 75%, and 85% for oxaliplatin, irinotecan, 5FU bolus, and 5FU intravenous infusion, respectively...Similar results were observed for the objective response. Pragmatic dose adjustments of FOLFIRINOX should be made by oncologists without considering a loss of effect.
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Review, Journal:  How to rescue high-dose methotrexate induced nephrotoxicity and literature review about hemodiafiltration? (Pubmed Central) -  Aug 5, 2021   
    We report a patient who experienced nephrotoxicity after the HD-MTX infusions during the treatment for non-Hodgkin lymphoma (NHL) and received hemodiafiltration (HDF) with large dose of leucovorin (LV) to treat MTX intoxication...Although a large dose of LV was applied, the patient's condition did not improve. It was found that the HDF with large dose of LV to save the patient and steadily improved the patient's clinical condition.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Retrospective data, Journal:  Integrative meta-analysis for the identification of hub genes in chemoresistant colorectal cancer. (Pubmed Central) -  Aug 4, 2021   
    We identified several deregulated genes and we discovered HNF4A as a hub gene. We performed functional validation and observed that by targeting HNF4A, HCT116 cells were more sensitive toward both oxaliplatin and 5-fluorouracil significantly.  Our findings show that HNF4A could be a potential target in overcoming FOLFOX chemoresistance in colorectal cancer.
  • ||||||||||  oxaliplatin / Generic mfg., irinotecan / Generic mfg.
    Journal:  An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer. (Pubmed Central) -  Aug 4, 2021   
    FOLFIRINOX chemotherapy, a combination of folinic acid, 5-fluoruracil, irinotecan and oxaliplatin, has shown the greatest survival benefit for patients with advanced disease but is only indicated for those with good physical performance status due to its extreme off-target toxicity...The results revealed that tumours treated with the IRMB-OxLipo complex and ultrasound were 136% smaller than tumours treated with the same concentration of irinotecan/oxaliplatin but delivered in a conventional manner, i.e. as a non-complexed mixture. This suggests that UTMD facilitates a more effective delivery of irinotecan/oxaliplatin improving the overall effectiveness of this drug combination and to the best of our knowledge, is the first reported example of a microbubble-liposome complex used to deliver these two chemotherapies.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., dexamethasone injection / Generic mfg.
    Clinical, Journal:  A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy. (Pubmed Central) -  Aug 4, 2021   
    Based on this research, it is possible to find a more effective way to provide an accurate reference for clinical drug use than traditional therapeutic drug monitoring (TDM). Gradual dose de-escalation and discontinuation of prophylactic dexamethasone is feasible without compromising its antiemetic effect in older patients undergoing chemotherapy.
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Journal:  Quantification of Methotrexate in Human Serum Using Surface-Enhanced Raman Scattering-Toward Therapeutic Drug Monitoring. (Pubmed Central) -  Aug 4, 2021   
    Monitoring methotrexate (MTX), an anticancer drug, is critical since it is needed to follow the drug clearance rate and decide how to administer the rescue drug, leucovorin (LV), in order to avoid toxicity and even death...The developed detection method enables fast detection (10 min) and quantification of MTX from human serum (>90% accuracy). Furthermore, we show the potential of the developed method for TDM, when quantifying MTX from clinical samples, collected from patients who are undergoing high-dose MTX therapy.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Clinical, Clinical data, Journal:  Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. (Pubmed Central) -  Aug 3, 2021   
    The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy...Patients in a real-world setting treated with NAPOLI-1-based liposomal irinotecan doublet regimens at academic centers were older with poorer performance status compared to trial patients yet had similar outcomes and efficacy. Furthermore, liposomal irinotecan was frequently used in the 3L+ setting where no treatment has been approved and provided clinical benefit.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  History and emerging trends in chemotherapy for gastric cancer. (Pubmed Central) -  Aug 3, 2021   
    Second- and third-line chemotherapy regimens include taxanes, Ramucirumab (R-mab), and Nivolumab (N-mab), which have different mechanisms of action from first-line chemotherapy...For resectable gastric cancer, in Eastern countries, postoperative adjuvant chemotherapy has been successful, including S1, Docetaxel/S1 (DS), and Xeloda/Oxaliplatin (Xelox) regimens, whereas, in Western countries, the 5-FU/Leucovorin/Oxaliplatin/Docetaxel (FLOT) regimen was recently shown to be effective in the perioperative chemotherapy setting...Recent genomic understanding of gastric cancer proposed a diversity of molecular targets by molecular profiling. Such optimized chemotherapy regimens, according to the specific clinical situations, have been rigorously established for the best survival of advanced gastric cancer.
  • ||||||||||  dexamethasone / Generic mfg., methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Clinical, PK/PD data, Journal:  Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumors. (Pubmed Central) -  Jul 30, 2021   
    A single T42-MTX measurement permits the safe administration of HDMTX and an expedited discharge from the hospital within three days in more than 90% of children with ALL/LL. By aggressively following institutional clinical guidelines, HDMTX-related toxicities were low, and using covariates from the population pharmacokinetic model enabled the calculation of a rational dosage for this patient population for future clinical trials.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Trial completion:  Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer (clinicaltrials.gov) -  Jul 29, 2021   
    P3,  N=315, Completed, 
    By aggressively following institutional clinical guidelines, HDMTX-related toxicities were low, and using covariates from the population pharmacokinetic model enabled the calculation of a rational dosage for this patient population for future clinical trials. Not yet recruiting --> Completed